Skip to main content

Table 2 Summary of findings in 220 patients with SC2-GBS

From: Guillain-Barre syndrome in 220 patients with COVID-19

Number of papers retrieved: 95
Number of SC2-GBS: 220
Number of patients with SC2-GBS subtypes: AIDP (n = 118), AMAN (n = 18), AMSAN (n = 11), MFS (n = 7), PNC (n = 2), PCB (n = 1), BSE (n = 0)
Age range of patients: 8 to 94 years
Gender: male (n = 146), female (67)
Onset: after COVID-19 (n = 156), together with COVID-19 (n = 3), before COVID-19 (n = 6)
Latency between onset of COVID-19 and GBS: − 10 to + 90 days
Therapy: IVIG (n = 191), plasmapheresis (n = 15), steroids (n = 2), MV (n = 41)
Outcome: CR (n = 37), PR (n = 119), death (n = 12)
  1. CR Complete recovery; MV Mechanical ventilation; PR Partial recovery